Rheumatoid Arthritis
CombinatoRx drug candidate CRx-102 demonstrates positive Phase 2 results in rheumatoid arthritis
Published in Healthcare Finance, Tax and Law Weekly, December 6th, 2006
The trial compared CRx-102 plus a disease-modifying anti-rheumatic drug (DMARD) to placebo plus DMARD (control) in subjects with RA. In this trial, CRx-102 demonstrated statistically significant improvements on primary and secondary endpoints:
- CRP: 50% median reduction from baseline to day 42 compared to 19% with control (p=0.024)
- ACR 20: 63% response at day 42 compared to 30% with control (p=0.025)
- DAS28: -1.6 mean change...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
More Articles from Healthcare Finance, Tax and Law Weekly
- Behavior
Scientists at City University of New York, Department of Psychology target behavior - Business & Finance
Acadia Pharmaceuticals posts loss of $11.3 million - Business & Finance
Adams Respiratory Therapeutics reports 26% increase in income - Business & Finance
Advanced Life Sciences records net loss of $0.24 per share - Business & Finance
Amicas reports quarterly positive operating cash flow - Business & Finance
Angiotech Pharmaceuticals reports income of $0.19 per share - More from this issue of Healthcare Finance, Tax and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
